Olga A Rogachevskaya

Learn More
Afferent output in type II taste cells is mediated by ATP liberated through ion channels. It is widely accepted that pannexin 1 (Panx1) channels are responsible for ATP release in diverse cell types, including taste cells. While biophysical evidence implicates slow deactivation of ion channels following ATP release in taste cells, recombinant Panx1(More)
Mammalian taste cells of the type II release ATP, an afferent neurotransmitter, by employing unselective ATP-permeable ion channels. The molecular identity of these channels is not known with confidence, although evidence implicates certain channel proteins from the connexin and pannexin families as most likely candidates. Here we carried out the(More)
TRPM5 are ion channels belonging to the TRP family, which demonstrate a nonselective permeability for monovalent cations and are activated by an increase in the intracellular calcium level. TRPM5 are present in taste receptor cells of type II responsible for reception of bitter, sweet, and umami taste sensations. Knockout of the trpm5 gene in mice results(More)
Taste cells of type I express the polymodal receptor CASR previously found in a heterologous system to recognize bitter denatonium as a ligand. Here we studied responsiveness of the type I cells to a variety of sapid compounds using Ca2+ imaging. Taste cells were isolated from mouse CV papillae and loaded with Ca2+ dye Fluo-4. Type I cells were identified(More)
It was shown that physiological processes in taste buds (peripheral sensory gustatory organs in vertebrates) are realized with the involvement of several signal systems. In these structures, a number of “classical” neurotransmitters, including glutamate, serotonin, GABA, ATP, noradrenaline, and others, as well as receptors to these agents, were identified.(More)
Many drugs are cardiotoxic because they inhibit hERG K+ channels, thus prolonging the repolarization phase of the cardiomyocyte action potential giving rise to cardiac arrhythmias. Early detection of inhibiting effects of candidate drugs on the activity of K+ channels in cardiomyocytes is one of the main challenges in preclinical drug screening. The aim of(More)
  • 1